Submit a Revision

*your email :**
page name* : such as "Introduction", "Conclusion"..etc
<p> A 2006 report by Cole <em>et al </em>described the in vitro selection of resistant virus variants to retrocyclin RC-101 <a></a>[<a href="http://www.biology-online.org/kb/#B26">26</a>]. This drug is a cationic <span>θ</span>-defensin that inhibits HIV-1 entry by blocking 6-helix bundle formation in a similar manner to fusion inhibitors such as T20 and T1249 <a></a>[<a href="http://www.biology-online.org/kb/#B27">27</a>]. The resistant variants that emerged had mutations in HR1 and HR2 of gp41 as well as the CD4 binding domain of gp120 (C4 domain). It was noted that the HR1/HR2 double mutant, but also the HR1/HR2/C4 triple mutant, were not able to adequately infect cells in the absence of RC-101. Addition of RC-101 restored infectivity in a dose-dependent manner. Interestingly, the HR2 mutation is identical to the SKY (N126K) mutation that we reported in the T20-dependent virus <a></a>[<a href="http://www.biology-online.org/kb/#B1">1</a>]. </p> <p> Recently, a drug-enhancement phenotype was reported for an inhibitor-bound form of the CCR5 co-receptor <a></a>[<a href="http://www.biology-online.org/kb/#B28">28</a>]. HIV-1 infection can be inhibited by small molecules that target the CCR5 coreceptor and one of the most promising drugs is SCH-D (Vicriviroc) <a></a>[<a href="http://www.biology-online.org/kb/#B29">29</a>]. It was demonstrated that the fully SCH-D resistant viruses with mutations in the Env gene, enter target cells by recognition of the SCH-D bound form of CCR5. SCH-D does not inhibit these resistant viruses, and even enhances their infectivity modestly. </p>
Confirmation code: Enter the code exactly as it appears. All letters are case insensitive, there is no zero.